Dr. Elemer Piros

ROTH Capital Partners

Image: Dr. Elemer Piros

Elemer Piros has ranked among the top analysts in various surveys, including ranking as the top biotechnology analyst by the Wall Street Journal in 2006 and by the Financial Times in 2010, based on stock portfolio performance. He has served as a senior biotechnology analyst at Ladenburg Thalmann, and as a biotechnology research analyst with Spear, Leeds & Kellogg/Goldman Sachs. Before serving as an analyst, Piros spent eight years conducting research in biophysics, biochemistry and molecular biology at Cornell University and the University of California, Los Angeles. He holds a doctorate in neurosciences from UCLA, a bachelor's degree in biology from UCLA, and a bachelor's degree in mathematics and technology from Eotvos Lorand University in Budapest.

Recent Articles

Potential ROI With German Biopharma Co. Notable 10/27/2022

This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report.

Biopharma Target Price 10 Times Current 10/06/2022

Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current.

Biotech Co.'s Drug Showing 'Early Signs of Benefit' 10/06/2022

With this upcoming analysis, the board will determine whether the Phase 2b/3 trial may continue to completion, noted a ROTH Capital Partners report.

Interim Results From Phase 2b Trial Are 'Encouraging' 09/30/2022

Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.


Recent Quotes

"PVCT's phase 2 trial results for PV-10 are very encouraging."

— Dr. Elemer Piros, ROTH Capital Partners (6/26/12)
more >

"ONCS announced positive results in its single-arm phase 4 trial."

— Dr. Elemer Piros, Rodman & Renshaw (4/20/12)
more >

"ONCS' DNA IL-12 is one of the best characterized and potent anti-tumor cytokines."

— Dr. Elemer Piros, Rodman & Renshaw (4/11/12)
more >

"We maintain our Market Outperform rating for PVCT."

— Dr. Elemer Piros, Rodman & Renshaw (3/26/12)
more >



Due to permission requirements, not all quotes are shown.